{"entity":{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","aka":[],"tldr":"Ph-positive ALL is acute lymphoblastic leukaemia carrying the Philadelphia chromosome. It was once the worst kind and is now often the best-controlled, thanks to TKIs and blinatumomab.","summary":"BCR::ABL1-positive B-ALL, ~25% of adult B-ALL and rising with age. TKI (dasatinib or ponatinib) plus reduced-intensity chemotherapy or steroids alone induces remission in nearly all; PhALLCON showed ponatinib beats imatinib for MRD-negative remission (34.4% vs 16.7%); D-ALBA showed a chemotherapy-free dasatinib-blinatumomab regimen with 95% 18-month survival. Whether transplant in first remission is still needed for MRD-negative patients is the open question.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Philadelphia_chromosome","links":[{"label":"ClinicalTrials.gov NCT03589326: PhALLCON","url":"https://clinicaltrials.gov/study/NCT03589326"},{"label":"ClinicalTrials.gov NCT02744768: D-ALBA (GIMEMA LAL2116)","url":"https://clinicaltrials.gov/study/NCT02744768"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["bcr-abl"],"drugs":["ponatinib","dasatinib","blinatumomab","imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["phallcon","d-alba"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/ph-positive-all/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/"}],"target":[{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/"}],"drug":[{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/"},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/"},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/"}],"trial":[{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/"},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/"}],"pairing":[{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/"}],"idea":[{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/"}]}}